# REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

> **NCT03690869** · PHASE1,PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Relapsed Solid Tumor
- Refractory Solid Tumor
- Relapsed Central Nervous System Tumor
- Refractory Central Nervous System Tumor
- Diffuse Intrinsic Pontine Glioma
- High Grade Glioma

## Interventions

- **DRUG:** cemiplimab (monotherapy)
- **DRUG:** cemiplimab (maintenance)
- **RADIATION:** Conventional or hypofractionated
- **RADIATION:** Re-irradiation

## Key facts

- **NCT ID:** NCT03690869
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-24
- **Primary completion:** 2023-05-10
- **Final completion:** 2023-05-10
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690869, "REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT03690869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*